Pexidartinib

DRUG11 trials

Sponsors

Daiichi Sankyo, Cogent Biosciences, Inc., Daiichi Sankyo Co., Ltd., Centre Leon Berard, Memorial Sloan Kettering Cancer Center

Conditions

Advanced CancerAdvanced Solid TumorsColorectal CancerDrug Interaction PotentialGastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal TumorsGiant Cell Tumors of the Tendon SheathMetastatic Cancer

Early Phase 1

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

CompletedNCT04223635

Daiichi SankyoModerate Hepatic Impairment

Start: 2020-01-07End: 2020-10-02Updated: 2021-06-22

Phase 1

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

CompletedNCT02401815

Cogent Biosciences, Inc.Gastrointestinal Stromal Tumors

Start: 2015-03-06End: 2020-05-11Updated: 2025-02-14

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

CompletedNCT02734433

Daiichi Sankyo Co., Ltd.Advanced Solid Tumors

Start: 2016-06-30End: 2021-05-28Updated: 2022-04-25

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

CompletedNCT02777710

Centre Leon BerardAdvanced Cancer, Colorectal Cancer, Metastatic Cancer +1

Start: 2016-06-30End: 2019-12-31Updated: 2021-09-05

Effect of Probenecid on Pexidartinib Pharmacokinetics

CompletedNCT03138759

Daiichi SankyoPharmacokinetics in Healthy Volunteers

Start: 2017-02-27End: 2017-03-30Updated: 2017-05-03

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

CompletedNCT03158103

Memorial Sloan Kettering Cancer CenterGastrointestinal Stromal Tumor (GIST)

Start: 2017-04-15End: 2021-04-28Updated: 2021-04-30

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

CompletedNCT03291288

Daiichi SankyoDrug Interaction Potential

Start: 2018-02-26End: 2021-04-16Updated: 2021-05-14

Phase 2

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active, not recruitingNCT04703322

Daiichi Sankyo Co., Ltd.Tenosynovial Giant Cell Tumor

Start: 2021-03-15End: 2026-05-31Updated: 2026-03-04

Phase 3

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

CompletedNCT02371369

Daiichi SankyoGiant Cell Tumors of the Tendon Sheath, Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor

Start: 2015-05-11End: 2021-04-30Updated: 2022-05-11

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

Active, not recruitingNCT04488822

Daiichi Sankyo Co., Ltd.Tenosynovial Giant Cell Tumor

Start: 2020-09-25End: 2026-02-28Updated: 2025-09-09

Phase 4

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

CompletedNCT04526704

Daiichi SankyoTenosynovial Giant Cell Tumor

Start: 2020-10-20End: 2023-07-07Updated: 2024-12-30

Related Papers

A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor

Oncology and Therapy2025-08-212 citations

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

The Oncologist2025-07-015 citations

58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment

ESMO Open2024-03-01

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers

Science Translational Medicine2024-01-2438 citations

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.

Journal of Clinical Oncology2023-06-016 citations

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects

Clinical Pharmacokinetics2022-10-2011 citations

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics

The Journal of Clinical Pharmacology2022-03-055 citations

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.

2021-08-0136 citations

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors

JAMA Oncology2021-07-0837 citations

Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

The Oncologist2020-12-0954 citations

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

Cancer2020-11-1664 citations

Abstract 2020: Identification of abnormal CSF1 transcripts in tenosynovial giant cell tumors and dose-dependent increase in plasma CSF1 levels in response to pexidartinib treatment

Cancer Research2020-08-15

ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).

2020-08-0523 citations

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

2019-06-19338 citations

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Journal of Clinical Oncology2019-05-2045 citations

Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.

Journal of Clinical Oncology2019-05-204 citations

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.

2019-03-0252 citations

Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).

Journal of Clinical Oncology2018-05-2021 citations

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).

Journal of Clinical Oncology2018-05-208 citations

2 more papers not shown